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Abstract 
Embryonic stem (ES) cells have great potential in applications such as disease modeling, 
pharmacological screening and stem cell therapies. Up to date, there is no related report on 
the use of ES cells as tracking and contrast reagents of cancer cells in vivo. Herein we report 
that  DiR-labeled  murine  ES  cells  can  recognize  and  target  gastric  cancer  cells  in  vivo. 
DiR-labeled  murine  ES  (mES)  cells  (5×10
6)  were  intravenously  injected  into  gastric  tu-
mor-bearing mice. The biodistribution of DiR-labeled mES cells was monitored by IVIS im-
aging within 24 h. Major organs were harvested and analyzed by immunofluorescence staining 
and Western blotting. Chemotaxis assay was employed to investigate the chemotaxis of ES 
cells tracking cancer cells. Fluorescent imaging results showed that DiR-labeled mES cells 
targeted gastric cancer tissue in vivo as early as 10 min post-injection, reaching a peak at 2h 
post-injection. Immunofluorescence staining and Western blotting results showed gastric 
cancer tissues specifically expressed SSEA-1. In vitro migration tests confirmed that mES cells 
actively moved to test sites with different concentration of CXCL12 in a dose-dependent 
manner. In conclusion, DiR-labeled mES cells may be used for gastric cancer targeted imaging 
in vivo, and have great potential in applications such as identifying and imaging of early gastric 
cancer in near future. 
Key words: murine embryonic stem cells; gastric cancer cells; target imaging; migration; chemo-
taxis. 
Introduction 
Since the firstly isolation of the murine embry-
onic stem (mES) cells in the 1980s, ES cells show their 
pluripotent nature, differentiating into cell types of all 
primary  germ  lineages  [1–3].  In  recent  years,  re-
searchers have paid more and more attention on the in 
vivo  monitoring  and  therapy  potential  of  stem  cells 
[4–6].  Generally,  stem  cell  therapies  consist  of  two 
aspects, one is the in vivo targeted migration of stem 
cells to the target tissues, and another is the prolifera-
tion and differentiation of stem cells in the target tis-
sues to regenerate new organs [7–10]. Those applica-
tions have promising prospects in regenerative medi-
cine.  
Stomach malignancy is currently the fourteenth 
most  common  cancer  in  the  United  States  and  the 
second most common cancer in China [11, 12]. Gastric 
cancer is still the second most common cause of can-
cer-related death in the world. It remains difficult to 
Ivyspring  
International Publisher   Theranostics 2012, 2(6) 
 
http://www.thno.org 
619 
cure effectively even in Western countries, primarily 
because most patients are identified at the advanced 
stages of the malignancy [13]. Thus, early recognition 
and tracking of gastric cancer cells in vivo would be of 
particular significance. Our group has tried to estab-
lish an early gastric cancer pre-warning system since 
2005 [14]. We hoped to find early gastric cancer cells 
in vivo  by  multi-mode  targeted  imaging  techniques 
[15–18]. However, our efforts were stalled by a lack of 
specific gastric cancer biomarkers. This is one reason 
why the search for an alternative  way to recognize 
and track early gastric cancer cells in vivo has become 
a central subject in this field. 
Among all the imaging techniques, near-infrared 
(NIR)  imaging  and  bioluminescence  imaging  (BLI) 
have  become  the  most  popular  modalities  [19,  20]. 
NIR imaging has many advantages over other imag-
ing means, because it can penetrate biological tissues 
such as skin and blood more efficiently than visible 
light [21, 22]. BLI combined with NIR light has been 
found  to  enable  real-time  observation  of  stem  cell 
trafficking and in vivo gene transfer.  
DiR dye is a lipophilic, NIR fluorescent cyanine 
dye  ideal  for  staining  cytoplasmic  membrane.  The 
two long 18-carbon chains of DiR dye can insert into 
the cell membrane, resulting in specific and stable cell 
staining  with  negligible  dye  transfer  between  cells. 
The NIR property of DiR dye makes it ideal for in vivo 
imaging  because  of  significantly  reduced  autofluo-
rescence from the animal at higher wavelength [23]. In 
this study, mES cells were labeled with NIR DiR dyes, 
in vivo distribution of DiR-labeled mES cells (DiR-mES 
cells) was monitored by an IVIS imaging system, and 
the chemotaxis mechanism of ES cells tracking cancer 
cells was investigated. The significant finding is that 
tumor tissues or metastatic cancer cells in vivo can be 
tracked by using mES cells as tracking and contrast 
reagents.  
Materials and Methods 
All  animal  experiments  (NO.SYXK2007-0025) 
were approved by the Institutional Animal Care and 
Use Committee of Shanghai Jiao Tong University. 
Feeder-free cultured murine embryonic stem 
(mES) cells 
Murine embryonic stem (GFP-SV129, mES) cells 
were provided by the Shanghai Institute of Digestive 
Disease, Renji Hospital. The mES cells were cultured 
with  completed  medium,  which  is  composed  of 
Knockout-DMEM  (Gibco)  supplemented  with  fetal 
bovine serum (FBS, Gibco), non-essential amino acids 
(NEAA,  Gibco),  L-glutamine  (Gibco), 
β-mercaptoethanol  (Gibco)  and  recombinant  human 
leukemia inhibitory factor (LIF, Chemicon). The mES 
cells were routinely passaged every 2 days, and the 
medium  was  changed  on  alternate  days.  The  feed-
er-free mES cells were prepared by using the direct 
transition method:  mES cells  were split  onto  newly 
gelatinized plates without feeders and incubated for 
30  min,  and  then  the  supernatant  culture  medium 
were collected and transferred into newly gelatinized 
plates without feeders and cultured until mitosis. The 
mES cells were continuously cultured for three to four 
or more splits by this method to eliminate all feeders. 
Labeling mES cells with DiR and in vitro cell 
imaging 
The  mES  cells  were  washed  three  times  with 
PBS,  trypsinized  with  0.05%  trypsin-ethylene  dia-
minetetra acetic acid (EDTA; Gibco-Invitrogen). The 
mES cells were incubated with 3.5 μg/mL DiR buffer 
for 30 min at 37°C according to the protocol of Xeno-
Light  DiR  (Caliper  Lifesciences).  DiR-labeled  mES 
cells were used as the DiR(+) test group, mES cells 
which  were  not  incubated  with  DiR  were  washed 
with  PBS  (pH  7.0)  and  marked  with  DiR(-)  control 
group. Then the DiR(+) and DiR(-) cells were centri-
fuged for 3 min at 1000 rpm  and 4°C, and washed 
twice with PBS buffer and examined for viability us-
ing  a  Typan  Blue  Staining  Cell  Viability  Assay  Kit 
(Beyotime).  Finally,  DiR(+)  and  DiR(-)  cells(5×106) 
were  resuspended  in  0.2  mL  PBS  buffer,  and  per-
formed fluorescence imaging in a 96-well black cul-
ture dish by IVIS system under 710 nm of excitation 
and 760 nm of emission. The DiR(+) and DiR(-) cells 
were continuously cultured and imaged at 4, 8, 12, 
and 24 h after first imaging under the same imaging 
conditions.  The  intensity  of  the  region  of  interest 
(ROI) was plotted in units of the maximum number of 
photons  per  second  per  centimeter  square  per  ster-
idian (p/s/cm2/sr). In order to evaluate the changes 
of the fluorescent signals varied cell numbers, 1×106, 
1×105, 1×104, 1×103  and  1×102  DiR(+)  cells  were 
also counted and performed fluorescent imaging in a 
96-well black culture dish by IVIS system under 710 
nm of excitation and 760 nm of emission, the correla-
tion between the number of DiR(+) cells and the in-
tensity of fluorescent signals was plotted. 
Preparation of bioluminescence gastric cancer 
mouse models  
Male athymic nude mice (4 weeks old, 17 ± 2 g) 
were  obtained  from  the  Shanghai  LAC  Laboratory 
Animal  Co.  Ltd.,  Chinese  Academy  of  Sciences 
(Shanghai, China, SCXK2007-0005). Bioluminescence 
mouse  gastric  cancer  cell  lines  (MFC)  (1x106)  were 
injected subcutaneously into the right anterior flank Theranostics 2012, 2(6) 
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areas of the mice. Four weeks later, tumors grew to 
approximately  5  mm  in  diameter,  and  biolumines-
cence  images  of  gastric  cancer  mouse  models  were 
taken using an IVIS system with the exposure time of 
30 s. 
DiR-mES cells for targeted imaging of gastric 
cancer cells in vivo 
DiR-mES  cells  (5×106)  were  intravenously  in-
jected into the gastric cancer mouse models (n=3) as 
test  group.  In  control  group,  gastric  cancer  mouse 
models (n=3) were injected with DiR. These injected 
gastric cancer mouse models  were monitored using 
the  IVIS  system  at  0.5,  1,  2,  4,  6,  12,  and  24h 
post-injection  to  obtain  serial  fluorescence  images. 
The ideal filter conditions for DiR imaging were set at 
710 nm of excitation and 760 nm of emission. Identical 
illumination settings (e.g., lamp voltage, filter, expo-
sure  time)  were  used  in  all  animal  imaging  experi-
ments.  The  mice  were  imaged  at  all-time  points  at 
lateral,  supine  and  prone  positions.  Spleen,  liver, 
lung, kidney, heart, and tumor tissues were collected 
for ex vivo imaging at 24 h post-injection. Gray-scale 
photographic images and fluorescent images of each 
sample were analyzed and overlaid using Living Im-
age  software  (Xenogen,  Alameda,  CA).  Regions  of 
interest (ROI) were drawn over the signals, and av-
erage  radiant  efficiency  was  quantified  in 
p/s/cm2/sr. 
Immunofluorescence analysis and Western 
Blot analysis 
For histological evaluation, the mice in the test 
and  control  groups  were  euthanized  after  imaging. 
Tumors and major organs (spleen, liver, lung, kidney, 
and heart) were excised, frozen, embedded, and sec-
tioned into 8 µm slices. The expression of SSEA-1 in 
these  tissues  were  examined  under  a  fluorescence 
microscope  (Olympus  IX71)  after  performing  im-
munohistochemical staining of slices. GFP imaging of 
ultra-thin  slices  were  also  imaged  simultaneously. 
Meanwhile, the expression of SSEA-1 in tumor tissues 
were  evaluated  in  protein  level.  Tumor  tissues  and 
important  organs  (liver,  lung,  kidney,  spleen,  and 
heart) were excised and lysed in protein lysis buffer. 
Equal amounts of sample lysates were separated by 
sodium  dodecylsulfate  polyacrylamide  gel  electro-
phoresis  (SDS-PAGE)  and  electrophoretically  trans-
ferred  to  polyvinylidene  difluoride  (PVDF)  mem-
branes (Millipore). The membranes were blocked with 
0.1%  BSA  in  Tris-buffered  saline  Tween-20  (TBST) 
buffer  and  incubated  overnight  at  4°C  with  an-
ti-SSEA-1  antibody.  The  membranes  were  washed 
with  TBST  buffer  and  incubated  with  horseradish 
peroxidase-conjugated  secondary  antibodies.  En-
hanced  chemiluminescence  kits  were  used  (Amer-
sham, ECL kits). 
Chemotaxis analysis  
The number of CXCR4-positive cells among mES 
cells was analyzed using a flow cytometer. PE-labeled 
anti-CXCR4  antibody  (BioLegend)  was  used  to  sort 
for CXCR4-positive cells. Amount of CXCL12 in the 
culture supernatants of MFC cells was examined by 
enzyme-linked  immunosorbent  assay  (ELISA)  with 
commercial kits (R & D System). The migration ability 
of mES cells was evaluated using a 48-well modified 
Boyden  chamber.  The  polycarbonate  filter  (12 μm 
pore size, CN110416; Neuroprobe, Bethesda, MD) was 
precoated with fibronectin (5 μg/mL; Sigma Chemi-
cal, St Louis, MO). The mES cells were resuspended at 
5×105/mL in the appropriate medium supplemented 
with 10% FBS and seeded in the upper chamber. Re-
combinant  CXCL12  (R&D  System)  was  used  as  a 
chemoattractant  in  the  lower  compartment.  The 
chambers were incubated overnight at 37°C. Results 
were expressed as the percentage of migrating cells. 
Each experiment was performed in triplicate. 
Statistical Analysis 
All data were presented in this paper as means 
result  ±  S.D.  Statistical  differences  were  evaluated 
using the t-test and considered significance at P < 0.05 
level.  
 
Results and Discussion 
Morphological observation of cultured mES 
cells  
As shown in Fig.1A and  1C, GFP-SV 129 mES 
cells cultured on the feeder cells formed typical large 
colonies with long-ellipse or long-shuttle shape, mES 
cells exhibited small enchylema and big nucleoli with 
obvious stereoscopic traits and clear boundaries when 
cultured  with  feeder  cells.  It  also  had  strong  green 
fluorescence signals since this mES cell line carries the 
GFP marker, as shown in Fig.1B. Although mES cells 
in feeder-free layer also maintained a normal karyo-
type, remarkable changes in mES cell shape grown in 
a monolayer can be observed as shown in Fig.1D and 
1F, the feeder-free mES cells also have strong green 
fluorescence signal (Fig.1E). 
In vitro fluorescence imaging of DiR-mES cells 
The NIR property of DiR dye makes it ideal for in 
vivo imaging. After the mES cells were labeled with 
DiR,  DiR-mES  cells  (5×106)  were  resuspended  and Theranostics 2012, 2(6) 
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added into 96-well plate and performed fluorescence 
imaging at 0, 4, 8, 12, and 24 h, respectively. The re-
sults showed that the fluorescence signals of DiR(+) 
cells were stronger than that of DiR(-) cells. Although 
the  fluorescent  signals  decreased  over  the  time  as 
shown in Fig.2A, it have statistical significance com-
pared  to  the  DiR(-)  cells.  Meanwhile,  fluorescence 
imaging  of  different  concentrations  of  DiR(+)  cells 
were performed as shown in Fig.2B. The linear rela-
tionship  (r2=0.9939)  between  Fluc  activity  and  cell 
number confirms that the mES cells were successfully 
labeled with DiR dye. Fig.2C shows the result of try-
pan blue staining, which suggests that the DiR(+) mES 
cells had good viability similar with the DiR(-) mES 
cells. Fig.2D shows that DiR-mES cells grew very well 
after being labeled with DiR. These data highly sug-
gest that DiR-mES cells had good cellular bioactivity 
and were suitable for in vivo imaging and tracking.  
In vivo fluorescence imaging of DiR-mES cells 
in gastric cancer mouse models 
In order to assess the biodistribution of mES cells 
in bioluminescence gastric cancer nude mouse mod-
els.  DiR-GFP-mES  cells  were  intravenously  injected 
into  gastric  cancer  mouse  models  as  test  group.  In 
control group, gastric cancer mouse models were in-
jected with DiR dye. The distribution of DiR-mES cells 
in gastric cancer nude mouse models was monitored 
within 24 h by IVIS imaging system at lateral, supine 
and prone positions. As shown in Fig.3, fluorescent 
signals in subcutaneous tumor tissues in test group 
were clearly differentiated from the surrounding tis-
sues at 10 min post-injection at lateral position. Fluo-
rescent signals in tumor tissues gradually increased, 
reaching a maximum value at 2 h post-injection. The 
higher  tissue  to  background  ratio  (TBR)  value  sug-
gests  that  the  DiR-mES  cells  preferentially  accumu-
lated in tumor tissues and achieved their maximum 
value at 2 h post-injection. Conversely, no fluorescent 
signals could be observed in the tumor tissues in con-
trol  group.  In  addition,  the  in  vivo  imaging  of  the 
mouse models was performed at supine position and 
prone position as shown in Supplementary Material: 
Fig.S1. These results show that DiR-mES cells mainly 
located in the tumor tissues, and very few DiR-mES 
cells  located  in  the  liver,  lung  and  kidney  organs, 
similar to several reports [24-26].  
 
 
Fig.1 Fluorescence microscope images of the morphology of GFP-SV129 mES cells.(A) GFP-SV129 mES cells exhibited typical large 
colonies and clearly boundaries with feeder cells. (B) mES cells expressed strong green fluorescence. (C) Magnification of mES cells 
cultured on feeder cells. (D) Feeder-free culture of mES cells grew in monolayer. (E) Feeder-free culture of mES cells exhibited green 
fluorescence. (F) Magnification of feeder-free culture of mES cells. Theranostics 2012, 2(6) 
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Fig.2 (A) DiR-labeled mES cells were subjected to fluorescent imaging at different exposure time, the ratio of DiR-labeled mES cells to 
unlabeled mES cells shows that the DiR-mES cells had strong fluorescent signals within 24 h. (B) The quantitative analysis of fluorescence 
of DiR(+) cells showed a linear relationship (r2=0.9939) between Fluc activity and cell numbers. (C) Trypan blue staining shows that mES 
cells had good cell viability after being labeled with DiR. (D) mES cells grew very well after being labeled with DiR 24 h. Theranostics 2012, 2(6) 
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Fig.3 In vivo fluorescence images of gastric cancer mouse models at 10 min, 30 min, 1 h, 2 h, 4 h, 6 h, 10 h, 24 h post-injection DiR-mES 
cells at lateral position. It shows that tumor tissues had strong fluorescence signals after injection DiR-mES cells as shown in blue circles. 
The tissue to background ratio (TBR) values show that DiR-mES cells accumulated in the tumor tissues and reached peak value at 2 h 
post-injection. 
 
 
In  order  to  track  the  distribution  of  DiR-mES 
cells in gastric cancer mouse models, the gastric can-
cer mouse models were performed bioluminescence 
and fluorescence imaging at 6 h post-injection. Fig.4A 
shows  the  NIR  fluorescence  imaging  of  the  gastric 
cancer mouse models. Fig.4B shows the biolumines-
cence  imaging  of  the  gastric  cancer  mouse  models. 
Fig.4C is a combination image of bioluminescence and 
fluorescence imaging. These results fully confirm that 
DiR-mES  cells  could  migrate  to  the  tumor  tissues 
precisely. As shown in Fig.4D, the ex vivo fluorescence 
imaging of major tissues in test and control groups 
shows that DiR-mES cells mainly existed in the tumor 
tissue of the test group. No obvious fluorescent signal 
were detected in the spleen and heart tissues of the 
test and control group, and weak fluorescent signals Theranostics 2012, 2(6) 
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were found in the lung, kidney and liver tissues of the 
test group. The reason for fluorescent signals found in 
liver tissue may be as following: DiR-mES cells were 
cleared  from  circulation  by  the  liver  and  trapped 
within capillary beds in the liver [27]. As shown in 
Fig.4E, the radiant efficiency of tumor tissue in test 
group was the highest among all the tissues in the test 
and  control  groups,  which  further  confirm  that 
DiR-mES cells could preferentially accumulate in the 
tumor tissue and efficiently target and identify gastric 
cancer cells in gastric cancer mouse models. 
Pathological analysis of tumor tissues and 
important organs 
Pathological evaluation of excised major tissues 
including the liver, lung, spleen, kidney, heart,  and 
tumor  was  performed.  SSEA-1  is  a  specific,  highly 
expressed surface antigen of mES cells, so the tumor 
tissues must express SSEA-1 once the mES cells mi-
grated  into  the  tumor  tissues.  As  shown  in  Fig.5A, 
GFP and SSEA-1 fluorescent signals were significant 
observed from the ultra-thin tumor tissue slices of the 
test  group  after  performed  immunofluorescence 
staining,  and  green  fluorescence  signals  were  con-
sistent with fluorescent signals in the tumor tissues of 
the test group, no GFP and immunofluorescent sig-
nals were found in the tumor tissues of the control 
group.  Furthermore,  as  shown  in  Supplementary 
Material: Fig.S2, no fluorescent signal was observed in 
the liver, lung, spleen, heart and kidney tissues of the 
test group. These results fully suggest that mES cells 
could specifically target gastric cancer cells in vivo. 
Western blot analysis of gastric cancer tissues 
The expression of SSEA-1 in excised tumor tis-
sues  was  investigated  using  Western  blotting.  The 
β-actin protein was used as a reference. Fig.5B shows 
that SSEA-1 was highly expressed in the tumor tissues 
of the test group, while it did not express in the tumor 
tissues of the control group. This result suggests that 
mES cells mainly located in the tumor tissues in vivo. 
 
 
 
Fig.4 Optical imaging of DiR-mES cells in vivo/ex vivo. (A) Fluorescence imaging of gastric cancer mouse models at 6 h post-injection at 
lateral position; (B) Bioluminescence imaging of gastric cancer mouse models at 6 h post-injection at lateral position; (C) Combination 
image of fluorescence and bioluminescence imaging shows that DiR-mES cells could target the tumor tissues exactly. (D)Ex vivo fluorescent 
image of the dissected organs and tumors in the control group and test group at 24 h post-injection. (E)Radiant efficiency of the tissues in 
the test group and control group. 
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Fig.5 (A) Immunofluorescence analysis of the tumor tissues. (B) Western blot analysis of the tumor tissues. 
 
Possible mechanism of the migration of mES 
cells to gastric cancer cells 
Tumor-homing is a complex, multistep process 
in which many cells move from distant locations to a 
tumor  site.  Homing  mES  cells  may  be  activated  by 
specific signals, and they can travel through the cir-
culation, extravasate from vessels, migrate, and un-
dergo phenotypic changes when it finally reaches the 
tumor  site.  The  mechanism  might  be  similar  to  the 
metastatic  cascade  [28].  So  far,  the  process  of  tu-
mor-homing  associated  with  mES  cells  is  still  not 
clarified.  The  term  “tumor-homing”  indicates  any 
action in which cells travel from a distant location to a 
tumor site, indicating an active filopodia-based mo-
tion through a tumor or surrounding local microen-
vironment based on local chemoattractants might be 
involved [29–36]. For example, CXCR4-CXCL12 loop 
was in charge of metastasis of the breast cancer [37]. 
The  interaction  between  CXCL12  and  CXCR4  has 
been  implicated  in  the  bone  metastasis  in  prostate 
cancer [38]. The CXCL12/CXCR4 axis has been shown 
to be involved in the metastasis of non–small-cell lung 
cancer  cells  [39].  Thus,  we  speculate  that 
CXCL12-CXCR4 loop may be involved in the course 
of mES cells migrating to the gastric cancer cells  in 
vivo.  
As shown in Fig.6, flow cytometer analysis re-
sults show that the positive rate of CXCR4 expression 
was  9.46  %  in  mES  cells.  ELISA  results  show  that Theranostics 2012, 2(6) 
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amounts  of  CXCL12  in  the  culture  supernatant  of 
MFC  cells  were  7.2±0.7  ng/mL.  Cell  and  chemoat-
tractant dose-response curves show that CXCL12 in-
duced chemotaxis of mES cells in a dose-dependent, 
bell-shaped  manner  with  maximum  chemotactic  re-
sponse seen at 400 ng/mL of CXCL12. According to 
these results, we suggested a possible mechanism of 
mES  cells  migrating  to  gastric  cancer  cells  in  vivo. 
DiR-labeled mES cells enter the tail vein vessels, and 
then rapidly circulate into lung vessels. From there, 
they enter into artery vessels, circulating throughout 
the mouse body. Some mES cells enter the liver and 
are captured and endocytosed by the phagocyte, fi-
nally  are  trapped  in  the  liver.  High  amounts  of 
CXCL12 were found in the surrounding of the tumor 
tissue,  providing  a  strong  chemotactic  signal.  Since 
mES  cells  positive  expressed  CXCR4  receptor,  they 
are very sensitive to CXCL12 factor secreted by gastric 
cancer tissue, which triggers the rapid mES cells mi-
gration toward gastric cancer tissues. In the course of 
migration of mES cells to gastric cancer tissues, it is 
possible that some other chemokine factors are also 
involved, therefore, a comprehensive study evaluat-
ing other potential mechanisms is under way. 
Stem  cell  therapy  is  a  promising  method  for 
cancer treatment [40-42]. Especially in 2004, there is 
one research reported that when the human embry-
onic stem (hES) cells were transfected with an anti-
cancer  molecular  named  “TRAIL”,  the  transfected 
hES cells could migrate to the brain tumor site and 
significant  prevent  the  tumor  growth  [43].  The  tar-
geting ability is the key for stem cell therapy of tu-
mors. In this research, we clearly observed that mES 
cells have good ability of targeting gastric cancer. This 
discovery lays foundation for diagnosing early gastric 
cancer with embryonic stem cells.  
In  this  study,  our  results  indicate  that 
DiR-labeled  mES  cells  could  target  and  recognize 
cancer cells in vivo. In addition to gastric cancer mouse 
model,  nude  mouse  models  with  lung  cancer,  liver 
cancer, and prostate cancer were also prepared. It is 
found  that  DiR-labeled  mES  cells  could  target  and 
recognize those different cancer cells in vivo as well 
(data  not  shown).  However,  the  detailed  molecular 
mechanism  of  tumor  targeting  still  requires  further 
investigation.  
 
 
Fig.6 Analysis of chemotaxis. (A) Expression of CXCR4 in isotype control(a) and mES cells (b) were determined by flow cytometry. (B) 
Secretion of CXCL12 in MFC cells was measured by enzyme-linked immunosorbent assay. (C) Cell and chemoattractant dose-response 
curves. 
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Conclusions 
In conclusion, this is the first report showing that 
DiR-labeled mES cells can selectively migrate to gas-
tric cancer tissues in vivo and can be used for targeted 
NIR imaging of gastric cancer cells  in vivo. The lig-
and-receptor  combinations  of  CXCL12  and  CXCR4 
may be responsible for the migration of mES cells to 
the gastric cancer cells. Although the detailed mecha-
nism  still  requires  further  investigation,  we  believe 
that this phenomenon may be general in other tumor 
models. Therefore, it has great potential in imaging 
detection of early and metastatic cancer cells in the 
near future. 
Supplementary Material 
Fig.S1 – S2. http://www.thno.org/v02p0618s1.pdf 
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